U.S. Residential REITs Stock News

German American Bancorp (GABC) just posted its FY 2025 fourth quarter numbers, reporting revenue of US$94.0 million and EPS of US$0.95, supported by quarterly net income of US$35.7 million. The bank’s revenue moved from US$64.5 million in Q4 2024 to US$94.0 million in Q4 2025, while quarterly EPS increased from US$0.78 to US$0.95 over the same period, indicating a notably different earnings profile than a year ago. With a trailing 12 month net profit margin of 32% and a P/E above sector...

Brinker International (EAT) just posted Q2 2026 results with revenue of US$1.35 billion and basic EPS of US$2.23, alongside net income of US$99.5 million, setting the tone for how its restaurant footprint and sales trends are feeding into profitability. The company has seen quarterly revenue move from US$1.36 billion in Q2 2025 to US$1.43 billion in Q3 2025 and US$1.46 billion in Q4 2025, while basic EPS over that stretch ran from US$2.67 in Q2 2025 to US$2.68 in Q3 2025 and US$2.40 in Q4...

Teva Pharmaceutical Industries (NYSE:TEVA) has just posted its FY 2025 third quarter numbers, with revenue of US$4.5b and basic EPS of US$0.38, as the trailing 12 month line shows revenue of US$16.8b and basic EPS of US$0.62. Over recent quarters the company has seen revenue range from US$4.2b in Q4 2024 to US$4.5b in Q3 2025, while basic EPS moved from a loss of US$0.19 in Q4 2024 to a profit of US$0.38 in Q3 2025. This sets up a story where margin trends and the mix of products in late...

Polaris (PII) closed out FY 2025 with Q4 revenue of US$1.9b and a basic EPS loss of US$5.34, as net income excluding extra items came in at a loss of US$303.6m. Over recent quarters the company has seen revenue move from US$1.6b in Q1 2025 to US$1.9b in Q4 2025. Basic EPS shifted from a loss of US$1.17 in Q1 to a larger loss of US$5.34 in Q4, with trailing twelve month EPS at a loss of US$8.18 on US$7.2b of revenue. For investors, the headline takeaway is that top line scale sits against...

UP Fintech Holding recently drew increased attention as analysts raised earnings estimates and assigned it a favorable ranking based on those revised expectations. At the same time, options markets showed an unusually strong tilt toward calls and higher implied volatility, underscoring intensified positioning ahead of the company’s March earnings release, which has now passed. We’ll now examine how this surge in bullish options activity shapes UP Fintech Holding’s investment narrative for...

Lakeland Financial (LKFN) closed out FY 2025 with fourth quarter revenue of US$69.8 million and basic EPS of US$1.17, alongside trailing twelve month EPS of US$4.02. Over the past year, total revenue has moved from US$236.8 million on a trailing basis at the end of 2024 to US$257.2 million by the fourth quarter of 2025, while quarterly EPS shifted from US$0.94 in Q4 2024 to US$1.17 in Q4 2025. This gives investors a clear view of how the income line is tracking into the new year. With a...

Why Waters (WAT) is on investors’ radar today Waters (WAT) has been drawing attention after recent share price moves, with the stock roughly flat over the past month but showing a gain over the past 3 months and mixed longer term returns. See our latest analysis for Waters. Recent trading has cooled slightly, with a 7 day share price return of 2.94% and a 1 day move of a 1.30% decline. However, the 90 day share price return of 12.29% contrasts with a 1 year total shareholder return of a 4.74%...

If you are wondering whether Soleno Therapeutics' current share price reflects its true worth, this article walks through what the numbers can and cannot tell you about value. The stock closed at US$41.61, with recent returns showing a 4.5% decline over 7 days, a 12.5% decline over 30 days and an 11.8% decline year to date. Its 3-year return is very large. Recent coverage of Soleno has focused on its position in pharmaceuticals and biotech, as investors weigh how its pipeline and clinical...

Zydus Lifesciences is reported to be exploring the acquisition of a majority stake in Ardelyx (NasdaqGM:ARDX). Ardelyx has initiated a Phase 3 clinical trial of IBSRELA in chronic idiopathic constipation, aiming to expand the drug's use beyond its current indication. These developments come as Ardelyx trades at $7.89, with recent share price moves attracting fresh investor attention. For investors watching Ardelyx, the combination of M&A interest and pipeline progress makes this an active...

Northrop Grumman (NOC) closed FY 2025 with fourth quarter revenue of US$11.7b and basic EPS of US$9.99, alongside net income of US$1,427m, setting a clear marker for how the year wrapped up operationally. Over recent periods, quarterly revenue has ranged from US$9.5b to US$11.7b while EPS has moved between US$3.33 and US$9.99. This gives investors a solid run of data points to judge consistency and the latest step up in earnings power. With trailing twelve month EPS of US$29.14 and a net...

If you are wondering whether Coastal Financial at US$104.58 is still fairly priced or starting to look stretched, you are not alone. This article is here to help you frame that question clearly. The stock has pulled back recently, with a 4.7% decline over 7 days, a 10.5% decline over 30 days and a 7.7% decline year to date, after a 21.1% return over the past year and a very large gain over 5 years. Recent attention on Coastal Financial has focused on its role within the US regional banking...

If you are wondering whether GCM Grosvenor at around US$11.37 is priced attractively or not, this article walks through what the current share price might be implying about value. The stock is roughly flat year to date with a 0.6% return, after a 12.9% decline over the last 12 months and a 45.5% gain across the past 3 years, so recent moves may look very different depending on your holding period. Recent attention on alternative asset managers and listed managers in general has kept GCM...

Nucor (NUE) just closed out FY 2025 with fourth quarter revenue of US$7.7 billion and basic EPS of US$1.67, alongside net income of US$383 million, setting the tone for how investors read its latest steel cycle update. Over the past two reported fourth quarters, revenue has moved from US$7.1 billion in FY 2024 to US$7.7 billion in FY 2025, while basic EPS shifted from US$1.22 to US$1.67. This gives a clear view of how the top line and per share earnings have tracked through the year. With...

If you are wondering whether LendingClub's share price still offers value, the recent trading history gives you a clear starting point to assess what you might be paying for each dollar of fundamentals. The stock most recently closed at US$20.81, with returns of 4.5% over the last 7 days, 6.0% over 30 days, 8.8% year to date, 23.6% over 1 year, 114.8% over 3 years and 80.8% over 5 years. This frames the question of whether the current price fully reflects these moves. Recent coverage has...

If you are wondering whether Intellia Therapeutics at around US$14.83 is a bargain or a value trap, you are not alone. The stock has returned 15.6% over the last 7 days, 57.1% over the past month, 61.0% year to date, yet longer term holders have seen a 48.2% 1 year return alongside 65.1% and 79.0% declines over 3 and 5 years respectively. These sharp swings have come as Intellia Therapeutics stays in focus as a gene editing company in the biotech space. In this area, sentiment can shift...

Sanmina (SANM) has kicked off Q1 2026 with revenue of about US$3.2b and basic EPS of US$0.91, setting the tone for how its earnings story is shaping up this year. The company has seen quarterly revenue move from US$2,006.3m in Q1 2025 to US$3,189.7m in Q1 2026, while basic EPS shifted from US$1.20 to US$0.91 over the same period. Trailing 12 month EPS now sits at US$4.27 on revenue of US$9.3b. With trailing net margins thinner than last year and a large one off loss still in the rear-view...

If you are wondering whether Mosaic's current share price lines up with its underlying worth, you are not alone. That is exactly what this article will help you unpack. Recently, the stock has seen a 5.2% return over the last 7 days, 17.0% over the last 30 days, 13.7% year to date, 4.1% over the last year, while the 3 year return sits at a 37.4% decline and the 5 year return at 15.8%, which may have changed how investors view both its potential and its risks. These moves have come alongside...

MicroVision (NasdaqGM:MVIS) has agreed to acquire key assets from Luminar Technologies through a Section 363 bankruptcy sale process. The package includes intellectual property, critical inventory, engineering staff, and existing commercial contracts, subject to bankruptcy court approval. The transaction is tied to Luminar's ongoing bankruptcy proceedings and remains contingent on court and procedural milestones. MicroVision focuses on lidar sensors and advanced perception solutions for...

Mobileye Global (NasdaqGS:MBLY) has introduced a new "fast slow" AI system that splits safety critical driving tasks from non safety tasks, with the latter handled in the cloud for its robotaxi platform. The company is targeting removal of safety drivers by 2026 in its partnership with Volkswagen, using this AI architecture to support cost efficient and scalable operations. Mobileye has also acquired Menti Robotics, marking its entry into humanoid robotics and extending its AI and simulation...

Wondering whether Schneider National’s current share price reflects its real worth, or if the market is missing something you can see? The stock most recently closed at US$29.55, with returns of 2.6% over the past week, 8.3% over 30 days, 9.6% year to date, 0.3% over 1 year, 16.5% over 3 years, and 45.1% over 5 years. Recent coverage around Schneider National has focused on its positioning in the US trucking and logistics industry and ongoing interest in freight and supply chain efficiency...

If you are wondering whether American States Water is fairly priced or if there is hidden value at the current US$73.21 share price, you are not alone. The stock has been relatively steady recently, with a 0.2% return over the last 30 days and a 0.4% return over the past year, although the 3 year return of a 16.9% decline shows longer term holders have had a very different experience. Recent attention on regulated utilities and income focused names has kept American States Water on some...

MakeMyTrip (MMYT) is back in focus after its latest quarterly earnings and an update on a long running share buyback, giving investors fresh numbers on growth, profitability, and capital returns. See our latest analysis for MakeMyTrip. Despite the recent earnings update and progress on the long running buyback, the latest 1 day share price return of a 1.54% decline and 7 day share price return of a 15.85% decline show sentiment cooling. That weaker tone is also visible in the 30 day and year...

Stock Yards Bancorp (NasdaqGS:SYBT) has signed an agreement to acquire Field & Main Bancorp. The deal expands Stock Yards Bancorp's banking footprint into Western Kentucky. The transaction marks a new phase of geographic expansion for the company. Stock Yards Bancorp, the parent of Stock Yards Bank & Trust, focuses on commercial and consumer banking services, with a presence across several regional markets. By bringing Field & Main Bancorp into the fold, the company adds new customer...

Serve Robotics, NasdaqCM:SERV, announced the acquisition of Diligent Robotics, expanding from sidewalk delivery into indoor autonomous robotics for hospitals and other facilities. The deal brings Serve into the market for AI powered service robots that operate in clinical and indoor environments. Investors now have exposure to both outdoor delivery and indoor robotics through a single listed company. Serve Robotics, NasdaqCM:SERV, now trades at $12.77, with a 30 day return of 25.9% and a...